SynthesisPloS one2021
The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.
Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Global scientific trends in hypercholesterolemia research from 2003 to 2023: a data-driven bibliometric and visual analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Generic Versus Branded Atorvastatin: A Single-Center Comparative Analysis of Clinical Effectiveness and Post-Delisting Cost Savings in Saudi Arabia.Healthcare (Basel, Switzerland) · 2026Article
- Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia.The pharmacogenomics journal · 2026Review
- VB-84922 is a small molecule that inhibits ER-to-golgi transport of SREBPs-SCAP complexes.Frontiers in pharmacology · 2026Article
- Epidemiology and determinants of dyslipidemia in Iranian population: Results from the PERSIAN cohort.PloS one · 2026Article
- Cost-Effectiveness Analysis of Pitavastatin in Dyslipidemia: Vietnam Case.Healthcare (Basel, Switzerland) · 2025Article
- Preclinical evaluation of high-resolution CT,European journal of nuclear medicine and molecular imaging · 2025Article
- Albumin-Based Nanoparticles with Factorial Design as a Promising Approach for Remodeled Repaglinide: Evidence from In Silico, In Vitro, and In Vivo Evaluations.Pharmaceutics · 2025Article
- Cost-effectiveness of universal genetic screening for familial hypercholesterolemia in young adults aged 18-40 years in China.BMC medicine · 2025Article
- Association of social isolation and depressive symptoms with workplace productivity loss in a multi-ethnic Asian study.Scientific reports · 2024Article
- The economic burden of obesity in 4 south-eastern European countries associated with obesity-related co-morbidities.BMC health services research · 2024Article
- Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID-19 pandemic.Clinical cardiology · 2023Review
- Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia.Current atherosclerosis reports · 2023Review
- Economic burden of hypercholesterolemia in high risk of cardiovascular disease population in Mexico.Archivos de cardiologia de Mexico · 2023Article
- Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia andFrontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases pose a significant economic burden worldwide; however, a clear picture of the economic impact of ASCVD secondary to hypercholesterolemia is lacking. This study aiming at conducting a systematic review of the current literature to assess the economic impact of familial hypercholesterolemia (FH), non-familial hypercholesterolemia (non-FH) or mixed dyslipidemia. A literature search was performed in Medline/PubMed and Embase database up to September 1st, 2020, exploring evidence published from 2010. The literature review was conducted in accordance with PRISMA guidelines. To be included the studies must be conducted on people who have been diagnosed with familial hypercholesterolemia, non-familial hypercholesterolemia or mixed dyslipidemia, and report data/information on costs attributable to these conditions and their sequelae. A total of 1260 studies were retrieved. After reading the titles and abstract, 103 studies were selected for full reading and eight met the criteria for inclusion. All but one studies were published in the American continent, with the majority conducted in US. An observational design with a prevalence approach were used and all estimated the economic burden of CVD. Direct cost estimates as annual average health expenditure on all population, ranging from $17 to $259 million. Few studies assessing the economic impact of hypercholesterolemia are available in the literature and new researches are needed to provide a more updated and reliable picture. Despite this scarceness of evidence, this review adds important data for future discussion on the knowledge of the economic impact of hypercholesterolemia and costs of care associated to this condition, with important implication for public health researches and novel therapies implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.